Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities

Fan, Sijia; Wang, Hongling; Wu, Dean; Liu, Lu

doi:10.2478/acph-2023-0014

Abstract

SARS-CoV-2, a newly discovered coronavirus, has been linked to the COVID-19 pandemic and is currently an important public health issue. Despite all the work done to date around the world, there is still no viable treatment for COVID-19. This study examined the most recent evidence on the efficacy and safety of several therapeutic options available including natural substances, synthetic drugs and vaccines in the treatment of COVID-19. Various natural compounds such as sarsapogenin, lycorine, biscoclaurine, vitamin B₁₂, glycyrrhizic acid, riboflavin, resveratrol and kaempferol, various vaccines and drugs such as AZD1222, mRNA-1273, BNT162b2, Sputnik V, and remdesivir, lopinavir, favipiravir, darunavir, oseltamivir, and umifenovir, resp., have been discussed comprehensively. We attempted to provide exhaustive information regarding the various prospective therapeutic approaches available in order to assist researchers and physicians in treating COVID-19 patients.

References

K. Habas, C. Nganwuchu, F. Shahzad, R. Gopalan, M. Haque, S. Rahman, A. A. Majumder and T. Nasim, Resolution of coronavirus disease 2019 (COVID-19), Expert Rev. Anti-inf. Ther. 18(12) (2020) 1201–1211; https://doi.org/10.1080/14787210.2020.1797487
Search in Google Scholar Back to article
J. Y. Chung, M. N. Thone and Y. J. Kwon, COVID-19 vaccines: The status and perspectives in delivery points of view, Adv. Drug Deliv. Rev. 170 (2021) 1–25; https://doi.org/10.1016/j.addr.2020.12.011
Search in Google Scholar Back to article
K. G. Andersen, A. Rambaut, W. I. Lipkin, E. C. Holmes and R. F. Garry, The proximal origin of SARS-CoV-2, Nat. Med. 26 (2020) 450–452; https://doi.org/10.1038/s41591-020-0820-9
Search in Google Scholar Back to article
F. Almazán, I. Sola, S. Zuñiga, S. Marquez-Jurado, L. Morales, M. Becares and L. Enjuanes, Corona-virus reverse genetic systems: infectious clones and replicons, Virus Res. 189 (2014) 262–270; https://doi.org/10.1016/j.virusres.2014.05.026
Search in Google Scholar Back to article
M. Ciotti, M. Ciccozzi, A. Terrinoni, W. C. Jiang, C. B. Wang and S. Bernardini, The COVID-19 pandemic, Crit. Rev. Clin. Lab. Sci. 57(6) (2020) 365–388; https://doi.org/10.1080/10408363.2020.1783198
Search in Google Scholar Back to article
P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao and Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579(7798) (2020) 270–275; https://doi.org/10.1038/s41586-020-2012-7
Search in Google Scholar Back to article
F. Li, Structure, function, and evolution of coronavirus spike proteins, Annu. Rev. Virol. 3(1) (2016) 237–261; https://doi.org/10.1146/annurev-virology-110615-042301
Search in Google Scholar Back to article
D. Schoeman and B. C. Fielding, Coronavirus envelope protein: current knowledge, Virol. J. 16(1) (2019) Article ID 69 (22 pages); https://doi.org/10.1186/s12985-019-1182-0
Search in Google Scholar Back to article
WHO, Coronavirus (COVID-19) Dashboard; https://covid19.who.int; last access date November 16, 2022.
Search in Google Scholar Back to article
Y. A. Malik, Properties of coronavirus and SARS-CoV-2, Malays J. Pathol. 42(1) (2020) 3–11.
Search in Google Scholar Back to article
A. E. Gorbalenya, S. C. Baker, R. S. Baric, R. J. de Groot, C. Drosten, A. A. Gulyaeva, B. L. Haagmans, C. Lauber, A. M. Leontovich, B. W. Neuman, D. Penzar, S. Perlman, L. L. M. Poon, D. V. Samborskiy, I. A. Sidorov, I. Sola and J. Ziebuhr (Coronaviridae study group of the International committee on taxonomy of viruses), The species Severe Acute Respiratory Syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nature Microbiol. 5(4) (2020) 536–544; https://doi.org/10.1038/s41564-020-0695-z
Search in Google Scholar Back to article
A. Sundararaman, M. Ray, P. V. Ravindra and P. M. Halami, Role of probiotics to combat viral infections with emphasis on COVID-19, Appl. Microbiol. Biotechnol. 104(19) (2020) 8089–8104; https://doi.org/10.1007/s00253-020-10832-4
Search in Google Scholar Back to article
W.-J. Guan, Z.-Y. Ni, Y. Hu, W.-H. Liang, C.-Q. Ou, J.-X. He, L. Liu, H. Shan, C.-L. Lei, D. S. C. Hui, B. Du, L.-J. Li, G. Zeng, K.-Y. Yuen, R.-C. Chen, C.-L. Tang, T. Wang, P.-Y. Chen, J. Xiang, S.-Y. Li, J.-L. Wang, Z.-J. Liang, Y.-X. Peng, L. Wei, Y. Liu, Y.-H. Hu, P. Peng, J.-M. Wang, J.-Y. Liu, Z. Chen, G. Li, Z.-J. Zheng, S.-Q. Qiu, J. Luo, C.-J. Ye, S.-Y. Zhu and N.-S. Zhong (for the China medical treatment expert group for Covid-19), Clinical characteristics of coronavirus disease 2019 in China, New Engl. J. Med. 382(18) (2020) 1708–1720; https://doi.org/10.1056/NEJMoa2002032
Search in Google Scholar Back to article
W. Shah, T. Hillman, E. D. Playford and L. Hishmeh, Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline, BMJ 372(136) (2021) Article ID 372 (4 pages); https://doi.org/10.1136/bmj.n136
Search in Google Scholar Back to article
C. Huang, L. Huang, Y. Wang, X. Li, L. Ren, X. Gu, L. Kang, L. Guo, M. Liu, X. Zhou, J. Luo, Z. Huang, S. Tu, Y. Zhao, L. Chen, D. Xu, Y. Li, C. Li, L. Peng, Y. Li, W. Xie, D. Cui, L. Shang, G. Fan, J. Xu, G. Wang, Y. Wang, J. Zhong, C. Wang, J. Wang, D. Zhang and Bin Cao, 6-month consequences of COVID- 19 in patients discharged from hospital: a cohort study, Lancet 397(10270) (2021) 220–232; https://doi.org/10.1016/S0140-6736(20)32656-8
Search in Google Scholar Back to article
M. Zarei, D. Bose, M. Nouri-Vaskeh, V. Tajiknia, R. Zand and M. Ghasemi, Long-term side effects and lingering symptoms post COVID-19 recovery, Rev. Med. Virol. 32(3) (2022) e2289; https://doi.org/10.1002/rmv.2289
Search in Google Scholar Back to article
N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M. A. Müller, C. Drosten and S. Pöhlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181(2) (2020) 271–280; https://doi.org/10.1016/j.cell.2020.02.052
Search in Google Scholar Back to article
X. Ou, Y. Liu, X. Lei, P. Li, D. Mi, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Z. Xiang, Z. Mu, X. Chen, J. Chen, K. Hu, Q. Jin, J. Wang and Z. Qian, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nature Commun. 11(1) (2020) Article ID 1620 (12 pages); https://doi.org/10.1038/s41467-020-15562-9
Search in Google Scholar Back to article
R. Liu, H. Han, F. Liu, Z. Lv, K. Wu, Y. Liu, Y. Feng and C. Zhu, Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020, Clin. Chim. Acta 505 (2020) 172–175; https://doi.org/10.1016/j.cca.2020.03.009
Search in Google Scholar Back to article
P. R. Hsueh, L. M. Huang, P. J. Chen, C. L. Kao and P. C. Yang, Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus, Clin. Microbiol. Infect. 10(12) (2004) 1062–1066; https://doi.org/10.1111/j.1469-0691.2004.01009.x
Search in Google Scholar Back to article
Z. Li, Y. Yi, X. Luo, N. Xiong, Y. Liu, R. Sun, Y. Wang, B. Hu, W. Chen, Y. Zhang, J. Wang, B. Huang, Y. Lin, J. Yang, W. Cai, X. Wang, J. Cheng, Z. Chen, K. Sun, W. Pan, Z. Zhan, L. Chen, F. Ye, Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis, J. Med. Virol. 92(9) (2020) 1518–1524; https://doi.org/10.1002/jmv.25727
Search in Google Scholar Back to article
D. E. Gordon, G. M. Jang, Bouhaddou, J. Xu, K. Obernier, M. J. O’Meara, J. Z. Guo, D. L. Swaney, T. A. Tummino, R. Hüttenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett, M. Cakir, M. J. McGregor, Q. Li, Z. Z. C. Naing, Y. Zhou, S. Peng, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, W. Shen, Y. Shi, Z. Zhang, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, C. J. P. Mathy, T. Perica, K. B. Pilla, S. J. Ganesan, D. J. Saltzberg, R. Ramachandran, X. Liu, S. B. Rosenthal, L. Calviello, S. Venkataramanan, Y. Lin, S. A. Wankowicz, M. Bohn, R. Trenker, J. M. Young, D. Cavero, J. Hiatt, T. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, F. Roesch, T. Vallet, B. Meyer, K. M. White, L. Miorin, D. Agard, M. Emerman, D. Ruggero, A. García-Sastre, N. Jura, M. von Zastrow, J. Taunton, O. Schwartz, M. Vignuzzi, C. d’Enfert, S. Mukherjee, M. Jacobson, H. S. Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. Floor, J. S. Fraser, J. Gross, A. Sali, T. Kortemme, P. Beltrao, K. Shokat, B. K. Shoichet and N. J. Krogan, A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing, preprint, bioRxiv 2020, posted March 27, 2020; https://doi.org/10.1101/2020.03.22.002386 [update: D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. O’Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, T. A. Tummino, R. Hüttenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett., M. Cakir, M. J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. Mac Kain, L. Miorin, E. Moreno, Z. Z. C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C. J. P. Mathy, T. Perica, K. Bharath Pilla, S. J. Ganesan, D. J. Saltzberg, R. Rakesh, X. Liu, S. B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huan, Y. F. Liu, S. A. Wankowicz, M. Bohn, M. Safari, F. S. Ugur, C. Koh, N. S. Savar, Q. D. Tran, D. Shengjuler, S. J. Fletcher, M. C. O’Neal, Y. Cai, J. C. J. Chang, D. J. Broadhurst, S. Klippsten, P. P. Sharp, N. A. Wenzell, D. Kuzuoglu-Ozturk, H.-Y. Wang, R. Trenker, J. M. Young, D. A. Cavero, J. Hiatt, T. L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R. M. Stroud, A. D. Frankel, O. S. Rosenberg, K. A. Verba, D. A. Agard, M. Ott, M. Emerman, N. Jura, M. von Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. d’Enfert, S. Mukherjee, M. Jacobson, H. S. Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. N. Floor, J. S. Fraser, J. D. Gross, A. Sali, B. L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. García-Sastre, K. M. Shokat, B. K. Shoichet and N. J. Krogan, Nature 583(7816) (2020) 459–468 (+ 17 pages), https://doi.org/10.1038/s41586-020-2286-9]
Search in Google Scholar Back to article
P. K. Samudrala, P. Kumar, K. Choudhary, N. Thakur, G. S. Wadekar, R. Dayaramani, M. Agrawal and A. Alexander, Virology, pathogenesis, diagnosis and in-line treatment of COVID-19, Eur. J. Pharmacol. 883 (2020) Article ID 173375 (12 pages); https://doi.org/10.1016/j.ejphar.2020.173375
Search in Google Scholar Back to article
S. Angeletti, D. Benvenuto, M. Bianchi, M. Giovanetti, S. Pascarella and M. Ciccozzi, COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis, J. Med. Virol. 92(6) (2020) 584–588; https://doi.org/10.1002/jmv.25719
Search in Google Scholar Back to article
R. J. G. Hulswit, Y. Lang, M. J. G. Bakkers, W. Li, Z. Li, A. Schouten, B. Ophorst, F. J. M. van Kuppeveld, G.-J. Boons, B.-J. Bosch, E. G. Huizinga and R. J. de Groot, Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A, Proc. Natl. Acad. Sci. USA 116(7) (2019) 2681–2690; https://doi.org/10.1073/pnas.1809667116
Search in Google Scholar Back to article
Y. J. Park, A. C. Walls, Z. Wang, M. M. Sauer, W. Li, M. A. Tortorici, B. J. Bosch, F. DiMaio and D. Veesler, Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors, Nat. Struct. Mol. Biol. 26(12) (2019) 1151–1157; https://doi.org/10.1038/s41594-019-0334-7
Search in Google Scholar Back to article
J. Cui, F. Li and Z.L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17(3) (2019) 181–192; https://doi.org/10.1038/s41579-018-0118-9
Search in Google Scholar Back to article
S. Satarker and M. Nampoothiri, Structural proteins in Severe Acute Respiratory Syndrome Coronavirus-2, Arch. Med. Res. 51(6) (2020) 482–491; https://doi.org/10.1016/j.arcmed.2020.05.012
Search in Google Scholar Back to article
E. A. J. Alsaadi and I. M. Jones, Membrane binding proteins of coronaviruses, Future Virol. 14(4) (2019) 275–286; https://doi.org/10.2217/fvl-2018-0144
Search in Google Scholar Back to article
B. W. Neuman, B. D. Adair, C. Yoshioka, J. D. Quispe, G. Orca, P. Kuhn, R. A. Milligan, M. Yeager, and M. J. Buchmeier, Supramolecular architecture of severe acute respiratory syndrome corona-virus revealed by electron cryomicroscopy, J. Virol. 80(16) (2006) 7918–7928; https://doi.org/10.1128/JVI.00645-06
Search in Google Scholar Back to article
Y. T. Tseng, S. M. Wang, K. J. Huang, A. I. Lee, C. C. Chiang and C. T. Wang, Self-assembly of severe acute respiratory syndrome coronavirus membrane protein, J. Biol. Chem. 285(17) (2010) 12862–12872; https://doi.org/10.1074/jbc.M109.030270
Search in Google Scholar Back to article
Q. Huang, L. Yu, A. M. Petros, A. Gunasekera, Z. Liu, N. Xu, P. Hajduk, J. Mack, S.W. Fesik and E. T. Olejniczak, Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein, Biochemistry 43(20) (2004) 6059–6063; https://doi.org/10.1021/bi036155b
Search in Google Scholar Back to article
P. V’kovski, M. Gerber, J. Kelly, S. Pfaender, N. Ebert, S. Braga Lagache, C. Simillion, J. Portmann, H. Stalder, V. Gaschen, R. Bruggmann, M. H. Stoffel, M. Heller, R. Dijkman and V. Thiel, Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity--labeling, eLife 8 (2019) e42037; https://doi.org/10.7554/eLife.42037
Search in Google Scholar Back to article
X. Yan, Q. Hao, Y. Mu, K. A. Timani, L. Ye, Y. Zhu and J. Wu, Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein, Int. J. Biochem. Cell Biol. 38(8) (2006) 1417–1428; https://doi.org/10.1016/j.biocel.2006.02.003
Search in Google Scholar Back to article
Y. Zeng, L. Ye, S. Zhu, H. Zheng, P. Zhao, W. Cai, L. Su, Y. She and Z. Wu, The nucleocapsid protein of SARS-associated coronavirus inhibits B23 phosphorylation, Biochem. Biophys. Res. Commun. 369(2) (2008) 287–291; https://doi.org/10.1016/j.bbrc.2008.01.096
Search in Google Scholar Back to article
X. Lu, J. Pan, J. Tao and D. Guo, SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism, Virus Genes 42(1) (2011) 37–45; https://doi.org/10.1007/s11262-010-0544-x
Search in Google Scholar Back to article
Q. Wang, C. Li, Q. Zhang, T. Wang, J. Li, W. Guan, J. Yu, M. Liang and D. Li, Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42, Virol. J. 7 (2010) Article ID 99 (8 pages); https://doi.org/10.1186/1743-422X-7-99
Search in Google Scholar Back to article
M. Surjit, B. Liu, V. T. Chow and S. K. Lal, The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells, J. Biol. Chem. 281(16) (2006) 10669–10681; https://doi.org/10.1074/jbc.M509233200
Search in Google Scholar Back to article
B. Zhou, J. Liu, Q. Wang, X. Liu, X. Li, P. Li, Q. Ma and C. Cao, The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha, J. Virol. 82(14) (2008) 6962–6971; https://doi.org/10.1128/JVI.00133-08
Search in Google Scholar Back to article
T. R. Ruch and C. E. Machamer, The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus, J. Virol. 85(2) (2011) 675–685; https://doi.org/10.1128/JVI.01570-10
Search in Google Scholar Back to article
D. X. Liu, Q. Yuan and Y. Liao. Coronavirus envelope protein: a small membrane protein with multiple functions, Cell. Mol. Life Sci. 64(16) (2007) 2043–2048; https://doi.org/10.1007/s00018-007-7103-1
Search in Google Scholar Back to article
T. S. Fung and D. X. Liu, Post-translational modifications of coronavirus proteins: roles and function, Future Virol. 13(6) (2018) 405–430; https://doi.org/10.2217/fvl-2018-0008
Search in Google Scholar Back to article
M. Prajapat, P. Sarma, N. Shekhar, P. Avti, S. Sinha, H. Kaur, S. Kumar, A. Bhattacharyya, H. Kumar, S. Bansal and B. Medhi, Drug targets for corona virus: A systematic review, Indian J. Pharmacol. 52(1) (2020) 56–65; https://doi.org/10.4103/ijp.IJP_115_20
Search in Google Scholar Back to article
C. C. Posthuma, D. D. Nedialkova, J. C. Zevenhoven-Dobbe, J. H. Blokhuis, A. E. Gorbalenya and E. J. Snijder, Site-directed mutagenesis of the Nidovirus replicative endoribonuclease NendoU exerts pleiotropic effects on the arterivirus life cycle, J. Virol. 80(4) (2006) 1653–1661; https://doi.org/10.1128/JVI.80.4.1653-1661.2006
Search in Google Scholar Back to article
X. Deng, M. Hackbart, R. C. Mettelman, A. O’Brien, A. M. Mielech, G. Yi, C. C. Kao and S. C. Baker, Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages, Proc. Natl. Acad. Sci. USA 114(21) (2017) E4251–E4260; https://doi.org/10.1073/pnas.1618310114
Search in Google Scholar Back to article
Y. Kim, R. Jedrzejczak, N. I. Maltseva, M. Wilamowski, M. Endres, A. Godzik, K. Michalska and A Joachimiak, Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2, Protein Sci. 29(7) (2020) 1596–1605; https://doi.org/10.1002/pro.3873
Search in Google Scholar Back to article
C. C. Stobart, N. R. Sexton, H. Munjal, X. Lu, K. L. Molland, S. Tomar, A. D. Mesecar and M. R. Denison, Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity, J. Virol. 87(23) (2013) 12611–12618; https://doi.org/10.1128/JVI.02050-13
Search in Google Scholar Back to article
H. Wang, S. Xue, H. Yang and C. Chen, Recent progress in the discovery of inhibitors targeting coronavirus proteases, Virol. Sin. 31(1) (2016) 24–30; https://doi.org/10.1007/s12250-015-3711-3
Search in Google Scholar Back to article
A. J. te Velthuis, S. H. van den Worm and E. J. Snijder, The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension, Nucleic Acids Res. 40(4) (2012) 1737–1747; https://doi.org/10.1093/nar/gkr893
Search in Google Scholar Back to article
M. P. Egloff, F. Ferron, V. Campanacci, S. Longhi, C. Rancurel, H. Dutartre, E. J. Snijder, A. E. Gorbalenya, C. Cambillau and B. Canard, The severe acute respiratory syndrome-coronavirus replica-tive protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world, Proc. Natl. Acad. Sci. USA 101(11) (2004) 3792–3796; https://doi.org/10.1073/pnas.0307877101
Search in Google Scholar Back to article
M. Bouvet, A. Lugari, C. C. Posthuma, J. C. Zevenhoven, S. Bernard, S. Betzi, I. Imbert, B. Canard, J.-C. Guillemot, P. Lécine, S. Pfefferle, C. Drosten, E. J. Snijder, E. Decroly and X. Morelli, Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes, J. Biol. Chem. 289(37) (2014) 25783–25796; https://doi.org/10.1074/jbc.M114.577353
Search in Google Scholar Back to article
T. Rodrigues, D. Reker, P. Schneider and G. Schneider, Counting on natural products for drug design, Nat. Chem. 8(6) (2016) 531–541; https://doi.org/10.1038/nchem.2479
Search in Google Scholar Back to article
R. R. Pamuru, N. Ponneri, A. G. Damu and R. Vadde, Targeting natural products for the treatment of COVID-19 – An updated review, Curr. Pharm. Des. 26(41) (2020) 5278–5285; https://doi.org/10.2174/1381612826666200903122536
Search in Google Scholar Back to article
M. Boozari and H. Hosseinzadeh, Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies, Phytother. Res. 35(2) (2021) 864–876; https://doi.org/10.1002/ptr.6873
Search in Google Scholar Back to article
D. Silveira, J. M. Prieto-Garcia, F. Boylan, O. Estrada, Y. M. Fonseca-Bazzo, C. M. Jamal, P. O. Magalhães, E. O. Pereira, M. Tomczyk and M. Heinrich, COVID-19: Is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?, Front. Pharmacol. 11 (2020) Article ID 581840 (44 pages); https://doi.org/10.3389/fphar.2020.581840
Search in Google Scholar Back to article
L. Ang, H. W. Lee, A. Kim and M. S. Lee, Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines, Integr. Med. Res. 9(3) (2020) Article ID 100465 (5 pages); https://doi.org/10.1016/j.imr.2020.100465
Search in Google Scholar Back to article
A. Y. Fan, S. Gu and S. F. Alemi (Research group for evidence-based Chinese medicine), Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis, J. Integr. Med. 18(5) (2020) 385–394; https://doi.org/10.1016/j.joim.2020.07.008
Search in Google Scholar Back to article
A. D. Fuzimoto and C. Isidoro, The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?, Trad. Complement. Med. 10(4) (2020) 405–419; https://doi.org/10.1016/j.jtcme.2020.05.003
Search in Google Scholar Back to article
D. H. Zhang, K. L. Wu, X. Zhang, S. Q. Deng and B. Peng, In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus, J. Integr. Med. 18(2) (2020) 152–158; https://doi.org/10.1016/j.joim.2020.02.005
Search in Google Scholar Back to article
S. Kumar, P. Kashyap, S. Chowdhury, S. Kumar, A. Panwar and A. Kumar, Identification of phyto-chemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARSCoV-2) that are capable of inhibiting virus replication, Phytomedicine 85 (2021) Article ID 153317 (10 pages); https://doi.org/10.1016/j.phymed.2020.153317
Search in Google Scholar Back to article
A. Khan, M. Khan, S. Saleem, Z. Babar, A. Ali, A. A. Khan, Z. Sardar, F. Hamayun, S. S. Ali and D.-Q. Wei, Phylogenetic analysis and structural perspectives of RNA-dependent RNA-polymerase inhibition from SARs-CoV-2 with natural products, Interdiscip. Sci. 12(3) (2020) 335–348; https://doi.org/10.1007/s12539-020-00381-9
Search in Google Scholar Back to article
M. T. Islam, C. Sarkar, D. M. El-Kersh, S. Jamaddar, S. J. Uddin, J. A. Shilpi and M. S. Mubarak, Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data, Phytother. Res. 34(10) (2020) 2471–2492; https://doi.org/10.1002/ptr.6700
Search in Google Scholar Back to article
A. Shah, V. Patel and B. Parmar, Discovery of some antiviral natural products to fight against novel coronavirus (SARS-CoV-2) using an in silico approach, Comb. Chem. High Throughput Screen. 24(8) (2021) 1271–1280; https://doi.org/10.2174/1386207323666200902135928
Search in Google Scholar Back to article
M. Kandeel and M. Al-Nazawi, Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease, Life Sci. 251 (2020) Article ID 117627 (5 pages); https://doi.org/10.1016/j.lfs.2020.117627
Search in Google Scholar Back to article
S. Vardhan and S. K. Sahoo, In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19, Comput. Biol. Med. 124 (2020) Article ID 103936 (12 pages); https://doi.org/10.1016/j.compbiomed.2020.103936
Search in Google Scholar Back to article
R. Yu, L. Chen, R. Lan, R. Shen and P. Li, Computational screening of antagonists against the SARSCoV-2 (COVID-19) coronavirus by molecular docking, Int. J. Antimicrob. Agents 56(2) (2020) Article ID 106012 (6 pages); https://doi.org/10.1016/j.ijantimicag.2020.106012
Search in Google Scholar Back to article
T. Joshi, T. Joshi, P. Sharma, S. Mathpal, H. Pundir, V. Bhatt and S. Chandra, In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking, Eur. Rev. Med. Pharmacol. Sci. 24(8) (2020) 4529–4536; https://doi.org/10.26355/eurrev_202004_21036
Search in Google Scholar Back to article
H. M. Wahedi, S. Ahmad and S. W. Abbasi, Stilbene-based natural compounds as promising drug candidates against COVID-19, J. Biomol. Struct. Dyn. 39(9) (2021) 3225–3234; https://doi.org/10.1080/07391102.2020.1762743
Search in Google Scholar Back to article
S. Kumar, K. Thakur, B. Sharma, T. R. Bhardwaj, D. N. Prasad and R. K. Singh, Recent advances in vaccine development for the treatment of emerging infectious diseases, Indian J. Pharm. Ed. Res. 53(3) (2019) 343–354.
Search in Google Scholar Back to article
D. V. Mehrotra, H. E. Janes, T. R. Fleming, P. W. Annunziato, K. M. Neuzil, L. N. Carpp, D. Benkeser, E. R. Brown, M. Carone, I. Cho, D. Donnell, M. P. Fay, Y. Fong, S. Han, I. Hirsch, Y. Huang, Y. Huang, O. Hyrien, M. Juraska, A. Luedtke, M. Nason, A. Vandebosch, H. Zhou, M. S. Cohen, L. Corey, J. Hartzel, D. Follmann and P. B. Gilbert, Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials, Ann. Intern. Med. 174(2) (2021) 221–228; https://doi.org/10.7326/M20-6169
Search in Google Scholar Back to article
A. J. Marian, Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries, Cardiovasc. Pathol. 50 (2021) Article ID 107278 (11 pages); https://doi.org/10.1016/j.carpath.2020.107278
Search in Google Scholar Back to article
University of Oxford, Vaccine knowledge project, Authoritative information for all, COVID-19 vaccines, https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines; last access date November 5, 2022
Search in Google Scholar Back to article
WHO, The Moderna COVID-19 (mRNA-1273) Vaccine: What you Need to Know; https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know; last access date November 17, 2022
Search in Google Scholar Back to article
L. A. Jackson, E. J. Anderson, N. G. Rouphael, P. C. Roberts, M. Makhene, R. N. Coler, M. P. Mc-Cullough, J. D. Chappell, M. R. Denison, L. J. Stevens, A. J. Pruijssers, A. McDermott, B. Flach, N. A. Doria-Rose, K. S. Corbett, K. M. Morabito, S. O’Dell, S. D. Schmidt, P. A. Swanson, II, M. Padilla, J. R. Mascola, K. M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert, K. Cross, W. Buchanan, R. Pikaart-Tautges, J. E. Ledgerwood, B. S. Graham and J. H. Beigel (for the mRNA-1273 study group), An mRNA Vaccine against SARS-CoV-2 - Preliminary report, N. Engl. J. Med. 383(20) (2020) 1920–1931; https://doi.org/10.1056/NEJMoa2022483
Search in Google Scholar Back to article
S. Roest, R. A. S Hoek and O. C. Manintveld, BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting, N. Engl. J. Med. 384(20) (2021) 1968–1970; https://doi.org/10.1056/NEJMc2104281
Search in Google Scholar Back to article
E. Callaway, Russia announces positive COVID-vaccine results from controversial trial, Nature -News 11 Nov 2020; https://doi.org/10.1038/d41586-020-03209-0
Search in Google Scholar Back to article
K. Rajarshi, R. Khan, M. K. Singh, T. Ranjan, S. Ray and S. Ray, Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19, Gene 768 (2021) Article ID 145313 (9 pages); https://doi.org/10.1016/j.gene.2020.145313
Search in Google Scholar Back to article
L. Dong, S. Hu and J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther. 14(1) (2020) 58–60; https://doi.org/10.5582/ddt.2020.01012
Search in Google Scholar Back to article
R. K. Guy, R. S. Di Paola, F. Romanelli and R. E. Dutch, Rapid repurposing of drugs for COVID-19, Science 368(6493) (2020) 829–830; https://doi.org/10.1126/science.abb9332
Search in Google Scholar Back to article
D. Calina, A. O. Docea, D. Petrakis, A. M. Egorov, A. A. Ishmukhametov, A. G. Gabibov, M. I. Shtilman, R. Kostoff, F. Carvalho, M. Vinceti, D. A. Spandidos and A. Tsatsakis, Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review), Int. J. Mol. Med. 46(1) (2020) 3–16; https://doi.org/10.3892/ijmm.2020.4596
Search in Google Scholar Back to article
Y.-F. Tu, C.-S. Chien, A. A. Yarmishyn, Y.-Y. Lin, Y.-H. Luo, Y.-T. Lin, W.-Y. Lai, D.-M. Yang, S.-J. Chou, Y.-P. Yang, M.-L. Wang and S.-H. Chiou, A review of SARS-CoV-2 and the ongoing clinical trials, Int. J. Mol. Sci. 21(7) (2020) Article ID 2657 (19 pages); https://doi.org/10.3390/ijms21072657
Search in Google Scholar Back to article
S. Mulangu, L. E. Dodd, R. T. Davey, Jr., O. T. Mbaya, M. Proschan, D. Mukadi, M. L. Manzo, D. Nzolo, A. T. Oloma, A. Ibanda, R. Ali, S. Coulibaly, A. C. Levine, R. Grais, J. Diaz, H. C. Lane, J.-J. Muyembe-Tamfum (and the PALM writing group for the PALM consortium study team), A randomized, controlled trial of Ebola virus disease therapeutics, N. Engl. J. Med. 381(24) (2019) 2293–2303; https://doi.org/10.1056/NEJMoa1910993
Search in Google Scholar Back to article
U. S. Food and Drug Administration, FDA Approves First Treatment for COVID-19, October 22, 2020; https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19; last access date November 17, 2022.
Search in Google Scholar Back to article
P. K. Samudrala, P. Kumar, K. Choudhary N. Thakur, G. S. Wadekar, R. Dayaramani, M. Agrawal and A. Alexander, Virology, pathogenesis, diagnosis and in-line treatment of COVID-19, Eur. J. Pharmacol. 883 (2020) Article ID 173375 (12 pages); https://doi.org/10.1016/j.ejphar.2020.173375
Search in Google Scholar Back to article
S. Kumar, A. Sil and A. Das, Hydroxychloroquine for COVID-19: Myths vs facts, Dermatol. Ther. 33(6) (2020) e13857; https://doi.org/10.1111/dth.13857
Search in Google Scholar Back to article
H. Pertinez, R. K. R. Rajoli, S. H. Khoo and A. Owen, Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2, J. Antimicrob. Chemother. 76(8) (2021) 2121–2128; https://doi.org/10.1093/jac/dkab135
Search in Google Scholar Back to article
M.-Y. Liu, S. Wang, W.-F. Yao, H.-z. Wu, S.-N. Meng and M.-J. Wei, Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers, Clin. Ther. 31(4) (2009) 784–792; https://doi.org/10.1016/j.clinthera.2009.04.016
Search in Google Scholar Back to article
F. M. Shirazi, R. Mirzaei, S. Nakhaee, A. Nejatian, S. Ghafari and O. Mehrpour, Repurposing the drug, ivermectin, in COVID-19: toxicological points of view, Eur. J. Med. Res. 27(1) (2022) Article ID 21 (11 pages); https://doi.org/10.1186/s40001-022-00645-8
Search in Google Scholar Back to article

Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities

Abstract

Paradigm

My account